APA (7th ed.) Citation

S, S., L, M., J, T., M, N., A, C., L, L., . . . S, M. (2026). Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 82(2), e262. https://doi.org/10.1093/cid/ciaf565

Chicago Style (17th ed.) Citation

S, Serrano-Villar, et al. "Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 82, no. 2 (2026): e262. https://doi.org/10.1093/cid/ciaf565.

MLA (9th ed.) Citation

S, Serrano-Villar, et al. "Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 82, no. 2, 2026, p. e262, https://doi.org/10.1093/cid/ciaf565.